Fenofibrate May Reduce CVD in Statin-Treated T2DM Patients

Share this content:
The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes.
The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes.

HealthDay News — Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia, according to a study published online in JAMA Cardiology.

Marshal B Elam, MD, PhD, from the Memphis Veterans Affairs Medical Center and University of Tennessee Health Sciences Center, and colleagues examined whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes. A total of 4644 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study participants were followed for an additional 5 years, for a total of 9.7 years.

The researchers found that following completion of ACCORD, only 4.3% of study participants continued fenofibrate treatment. Among participants originally randomized to fenofibrate or placebo, high-density lipoprotein and triglyceride values rapidly equalized. During 9.7 years of follow-up, the hazard ratio for the primary study outcome (composite of fatal and nonfatal myocardial infarction and stroke) among participants originally randomized to fenofibrate versus placebo (hazard ratio, 0.93; 95% CI, 0.83 to 1.05; P = 0.25) was comparable with that originally seen in ACCORD (hazard ratio, 0.92; 95% CI, 0.79 to 1.08; P = 0.32). For participants with dyslipidemia, fenofibrate therapy effectively reduced CVD (hazard ratio, 0.73; 95% CI, 0.56 to 0.95).

"The continued observation of heterogeneity of treatment response by baseline lipids suggests that fenofibrate therapy may reduce CVD in patients with diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; several pharmaceutical companies provided study medications, equipment, and supplies during ACCORD.

Reference

  1. Elam MB, Ginsberg HN, Lovato LC, et al. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol. 28 December 2016. doi: 10.1001/jamacardio.2016.4828.

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup